How do I install the Endo Dhea Generalized Use Against skill?

Run npx skillmds@latest add dromlakhani/endo-dhea-generalized-use-against in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Dhea Generalized Use Against safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Dhea Generalized Use Against?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Dhea Generalized Use Against free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Dhea Generalized Use Against?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Dhea Generalized Use Against by dromlakhani

Name: Endo Dhea Generalized Use Against
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Dhea Generalized Use Against

Recommends against routine use of dehydroepiandrosterone in women because indications are inadequate and evidence of efficacy and long-term safety is lacking. Triggers include a clinician considering DHEA supplementation for general well‑being, adrenal insufficiency, or other non‑specific indications.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Recommend against generalized DHEA use in women

STEP 1 — Gather Information

Collect the reason for considering DHEA (e.g., fatigue, low libido, general well‑being), any specific medical condition (adrenal insufficiency, hypopituitarism, surgical menopause), baseline DHEAS/DHEA if available, current therapies, and signs of androgen excess.

STEP 2 — Rule In / Rule Out

Is the indication a generalized, non‑specific goal (e.g., general well‑being, aging, fatigue without a defined endocrine deficiency)? If yes → recommend against DHEA (proceed to STEP 4). If the indication is a specific condition (adrenal insufficiency, hypopituitarism, etc.) → proceed to STEP 3.

STEP 3 — Classify or Stratify

For specific indications, classify as “limited evidence”: data on efficacy and long‑term safety are insufficient; routine use is not supported, but a short‑term, monitored trial may be considered only after shared decision‑making.

STEP 4 — Decide

Recommend against routine DHEA use. If a specific indication is present and the patient insists, discuss the lack of evidence, obtain informed consent, consider a short‑term (e.g., 3‑month) trial with clinical monitoring for efficacy and androgenic side effects, and plan to discontinue if no benefit.

Clinical Guardrails / Mimics / Pitfalls

Do not prescribe DHEA for general well‑being or aging‑related symptoms; avoid long‑term (>6 months) use without clear benefit; do not substitute DHEA for glucocorticoid replacement in adrenal insufficiency; monitor for virilizing effects (acne, hirsutism, voice changes) if used; do not rely on DHEA to treat infertility, cognitive decline, cardiovascular risk, or bone health.

Concrete Clinical Example

A 48‑year‑old woman with stable glucocorticoid‑replaced primary adrenal insufficiency reports persistent fatigue and low mood. Her clinician considers DHEA 25 mg daily. Following the guideline, the clinician discusses the inadequate evidence, decides against routine DHEA, optimizes glucocorticoid dosing, screens for depression, and initiates aerobic exercise instead.

Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, American Society for Reproductive Medicine, American College of Obstetricians and Gynecologists, European Society of Endocrinology, International Menopause Society, 2014, DOI:10.1210/jc.2014-2260

---name: endo-dhea-generalized-use-againstdescription: Recommends against routine use of dehydroepiandrosterone in women because indications are inadequate and evidence of efficacy and long-term safety is lacking. Triggers include a clinician considering DHEA supplementation for general well‑being, adrenal insufficiency, or other non‑specific indications.---# Recommend against generalized DHEA use in women## STEP 1 — Gather InformationCollect the reason for considering DHEA (e.g., fatigue, low libido, general well‑being), any specific medical condition (adrenal insufficiency, hypopituitarism, surgical menopause), baseline DHEAS/DHEA if available, current therapies, and signs of androgen excess.## STEP 2 — Rule In / Rule OutIs the indication a generalized, non‑specific goal (e.g., general well‑being, aging, fatigue without a defined endocrine deficiency)? If yes → recommend against DHEA (proceed to STEP 4). If the indication is a specific condition (adrenal insufficiency, hypopituitarism, etc.) → proceed to STEP 3.## STEP 3 — Classify or StratifyFor specific indications, classify as “limited evidence”: data on efficacy and long‑term safety are insufficient; routine use is not supported, but a short‑term, monitored trial may be considered only after shared decision‑making.## STEP 4 — DecideRecommend against routine DHEA use. If a specific indication is present and the patient insists, discuss the lack of evidence, obtain informed consent, consider a short‑term (e.g., 3‑month) trial with clinical monitoring for efficacy and androgenic side effects, and plan to discontinue if no benefit.## Clinical Guardrails / Mimics / PitfallsDo not prescribe DHEA for general well‑being or aging‑related symptoms; avoid long‑term (>6 months) use without clear benefit; do not substitute DHEA for glucocorticoid replacement in adrenal insufficiency; monitor for virilizing effects (acne, hirsutism, voice changes) if used; do not rely on DHEA to treat infertility, cognitive decline, cardiovascular risk, or bone health.## Concrete Clinical ExampleA 48‑year‑old woman with stable glucocorticoid‑replaced primary adrenal insufficiency reports persistent fatigue and low mood. Her clinician considers DHEA 25 mg daily. Following the guideline, the clinician discusses the inadequate evidence, decides against routine DHEA, optimizes glucocorticoid dosing, screens for depression, and initiates aerobic exercise instead.**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, American Society for Reproductive Medicine, American College of Obstetricians and Gynecologists, European Society of Endocrinology, International Menopause Society, 2014, DOI:10.1210/jc.2014-2260

Frequently asked questions